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Summary
DBA/2 mice were injected intravenously with 2 x 106 3C18 Friend erythroleukemia cells (FLC),
a cell line resistant to interferon ac/R (IFN-a/a) . Although daily administration ofmouse IFN-
cx/o markedly increased the mean survival time, most IFN-treated mice continued to harbor
FLC in different organs . To investigate the mechanisms responsible for this persistent suppression
of FLC growth in IFN-treated mice, we undertook a series of adoptive transfer experiments
with sera and spleen cells. Sera from FLC-injected, IFN-treated mice were very effective in conferring
protection on DBA/2 mice even when injected systemically (intravenously) 18-24 h before
intravenous challenge with FLC. These sera also exhibited antitumor activity when injected
subcutaneously or intraperitoneally together withFLC. The protective factor in serum wasshown
to be an immunogloblin . FLC-injected, IFN-treated mice developed antibodies toFLC demonstrable
by radioimmunoassay and complement-dependent cytotoxicity. Sera from these mice recognized
a specific 65-kD FLC membrane antigen(s) not detectable on membrane extracts from RBLr5
or ESb tumor cells, or on normal spleen cells . FLC-injected, IFN-treated mice also developed
a specific cellular response demonstrable by transfer of protection with spleen cells injected
intravenously or subcutaneously. Analysis of the responsible spleen cell populations indicated
that the effector cells were neither T nor B cells . These results demonstrating the importance
of host humoral and cellular immune mechanisms in the persistent suppression of FLC in IFN-
treated mice may be relevant to the use of IFN-oi//3 in patients in whom tumors may regress
and tumor cells may then remain latent for extended periods of time .
W
e have been interested in how IFN inhibits tumor
growth and especially how it inhibits the develop-
ment of tumor metastases . Using an experimental mouse
model, we showed that IFN-a/(3 treatment was very effec-
tive in inhibiting the development of Friend erythroleukemia
cell (FLC)t metastases and in increasingmouse survival time
(1, 2) . Use of IFN-ot// .-resistant lines ofFLC indicated that
IFN was most likely not acting directly on the tumor cells
themselves (3-6), but acted through host mechanisms (1),
and our previous experiments emphasized the importance of
1 Abbreviations used in thispaper. FLC, Friend erythroleukemia cell ; NDV,
Newcastle disease virus; VSV, vesicular stomatitis virus .
an intact immune system in achieving optimal therapeutic
effects (7) .
In the months after injection of tumor cells, it became ap-
parent thatFLC often remained latent in different organs even
after IFN treatment had been discontinued . These observa-
tions suggested that either the phenotype of tumorigenicity
of residual FLC had changed or that IFN-treated mice devel-
oped means of restraining FLC tumor growth . As our ex-
perimental results showed that FLC recovered from the livers
of surviving IFN-treated mice still conserved their tumori-
genic and metastatic capacity, we investigated the nature of
possible host mechanisms. The results of the experiments
presented herein show that FLC-injected, IFN-treated mice
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that we believe are responsible for the persistent suppression
of FLC growth in these mice.
Materials and Methods
Mice
DBA/2 mice were obtained from the pathogen-free breeding
colony of the Institut de Recherches Scientifiques sur le Cancer
(Villejuif).
Tumor Cells
The IFN-odo-resistant clone3C18 of FLC, obtained from Dr.
E. Affabris (3) (Istituto Superiore di Saniti, Rome, Italy), was pas-
saged in our laboratoryby weeklyintraperitoneal injection ofDBA/2
mice. These cells were highly metastatic for the liver and spleen
(8-10) .Thephenotype ofIFN resistance of308FLCwasconfirmed
several times in the course of these experiments by cultivating in
vivo passaged cells in the presence of IFN-cce//3 (4). TheESb lym-
phoma, a spontaneous metastatic variant ofa methylcholanthrene-
inducedT cell lymphoma (11), wasobtained fromV Schirrmacher
(Heidelberg, FRG) and was passaged intraperitoneally in DBA/2
mice . RBL5 tumor cells, a Rauscher virus lymphoma line, were
originally provided by J.P. Livy (Paris, France) and passaged in-
traperitoneally in C57B1/6 mice.
Quantitation of Tumor Growth
Intravenous.
￿
Mice injectedintravenously with FLC die with mac-
roscopic tumor invasion of the liver and spleen . The mean day of
death ofDBA/2 mice injected intravenously with serial 10-fold di-
lutions of3C18FLC is highly reproducible, and the standard error
is very small. As can be seen in Fig. 1, the mean dayof death for
mice injected intravenouslywith 105 FLCwas 12.4 ± 0.4 and 17.4
± 0.6 d for mice injected with 102 FLC (i .e., a difference of 1,000-
fold in the number of FLC injected can be equated with a N5-d
difference in themean day ofdeath) . Approximately fourFLCcon-
stituted one LD50 (1) .
Subcutaneous.
￿
DBA/2 mice were shaved and 24 h later injected
in the dorsal shoulder region with 3C18 FLC. The diameter of
tumor nodules was measured with callipers .
Intraperitoneal.
￿
Mice were killed and the peritoneal cavity was
washed with 2 ml of cold RPMI containing 2% FCS . The total
number ofcells recovered from each mousewasestimatedby colony
formation in agarose (4) .
IFN-al# and Control Preparations
MouseIFN-a/R was prepared from suspension cultures of mouse
sarcoma C243 cells infected with Newcastle disease virus (NDV).
The methods of production, partial purification, and assay have
previously been described (12) . Control preparations consisted of
the supernatant from cultures of C243 cells in which the IFN in-
ducer, NDV, wasomitted . IFN and control preparations were then
concentrated 50-fold . IFNwas assayed by inhibition ofcytopathic
effect of vesicular stomatitis virus (VSV) on L cells in monolayer
cultures (0.2 ml/well) in microplates (Falcon Labware, Oxnard,
CA) . Units are expressed in mouse reference units. The specific
activity of partially purified IFN was v2 x 101 U/mg protein .
Titration of Antibodies to FLC in the Sera of
FLC-injected, IFN-treated DBA/2 Mice
Radioimmunoassay .
￿
50 pl oftwofold serial dilutions ofsera was
added to 3C18 FLC (5 x 10' cells in 50 N .l of PBS containing 1
mg/ml ofBSA[PBS-BSA]) in Millititer'SV 96-well filtration plates
(SVLP5.0,um hydrophilic durapore; Millipore Continental Water
Systems, Bedford, MA). After 1 h at 4°C, cells were washed four
times with 200 Al/well of PBS-BSA, using a filter apparatus (Mil-
lititer''"; Millipore Continental Water Systems) anda suction pump.
100 pl containing ti105 cpm of anti-mouse Ig, '2'I-labeled species-
specific F(ab)2 fragment (Amersham Corp., Arlington Heights,
IL), was added to each well . After 1 h ofincubation at 4°C, cells
were washed extensively . Dried filters were removed and counted
for cell-bound radioactivity in agammacounter(Beckman Instru-
ments, Inc., No Alto, CA). Pooled sera from normal untreated
mice were used as a negative control in each test . Triplicate samples
for each serum dilution were used . The end-point dilution of a
given serum exhibiting an anti-FLC reactivity significantly higher
than the corresponding dilution of normal control serum (p<0.01)
was estimated as the specific anti-FLC titer.
Complement-mediated Cytotoxicity
Specific cytotoxic activity of sera was assessed in a chromium
release assay. FLCfrom tumor ascites were radiolabeled by incuba-
tion of 5 x 10 6 FLC with 200 /ACi of 5t[Cr] sodium chromate
(2 mCi/ml; CEA/ORIS, Gif sur Yvette, France) for 1 h at 37°C
in 0.5 ml RPMI 1640 plus 5% FCS and then washed extensively.
10' labeled target cells were incubated in round-bottomed
microplates (Nunc, Roskilde, Denmark) with serial twofold dilu-
tions of serum in 0.2 ml total volume at 4°C for 1 h and subse-
quentlywith rabbit complement diluted 1:30 for30 min at 37°C;
0.1 ml of supernatant was collected at the end of the incubation
period and counted for gamma radioactivity. The percentage of
cytotoxicity was calculated with the following formula : 100x [(cpm
released in serum + C - cpm released in C)/(cpm released in
detergent - cpm released in C)] .
Identification by Western Blot ofFLC Membrane Proteins
Recognized by Antibodies in the Sera of FLC-injected,
IFN-treated Mice
Cell membrane fractions were prepared by sucrose gradient as
previously described (13, 14) . The protein content of cell mem-
brane fractions was assayed by the method of Lowry et al . (15) .
The NP-40 membrane protein fractions (corresponding to 107
cells) were diluted 1:1 with sample buffer (1% SDS, 2% mercap-
toethanol, 1:10 electrode buffer, 10% glycerol), boiled for4 min,
andloaded onto a 10% acrylamide-SDS slab gel. After electropho-
resis, proteins were transferred onto nitrocellulose membranes for
4 h at 250mA . Nitrocellulose membraneswere saturatedby incu-
bation with 2% BSA in PBS for 1 h at room temperature . Strips
were incubated overnight at 4°C with different sera diluted 1:100
in PBS containing 2% BSA. After washing with PBS containing
0.2% BSA and 0.1% NP-40, the strips were incubated with i
gCi/ml '251-labeled anti-mouse Ig (Fab fragment), for 2-4 h at
room temperature. The nitrocellulose strips were exposed at -80°C
for 2-12 h with an intensifying screen .
Separation of Ig Fraction from Sera with Antitumor Activity
Protein A-Sepharose 4B (Pharmacia Fine Chemicals, Uppsala,
Sweden) was prewashed in a 40-mM Hepes buffer solution, pH
8.0 . As a control, BSA was coupled to activated Sepharose 4B (7
mg/ml in Hepes 40 mM, pH 8.0) . Potential sites of nonspecific
binding were blocked with 1 M ethanolamine, pH 8.0, for 2 h
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by anion exchange chromatography are given in the legend to
Table 1 .
Preparation of Splenic Cells and Cell Fractionation
Spleen cell suspensions were prepared aseptically in RPMI 1640
and2% FCS . After sedimentation ofclumps oftissue, the cell-rich
supernatant was filtered on a loose-meshed nylon gauze, the cell
suspension centrifuged, and the cell pellet resuspended . For cell
fractionation, pooled spleen cells from several mice were prepared
aseptically. T, B, and nul cell subsets were separated by negative
panning selection (16) . 5 x 10' splenocytes were incubated for 40
min at 4°C over Petri dishes precoatedwith antibodies (10,ug/ml
ofIg-purified fractions from serum or ascites) . After agitation, the
nonadherent cells were carefully pipetted, washed three times, and
counted. Cell aliquots were stained with fluoresceinated antibodies
andanalyzed by flow cytometry (FacsScan ; Becton Dickinson &
Co ., Mountain View, CA) for monitoring cell depletion . Antibodies
used for depletion were clone 4.221 against Thy-1.2* cells (17),
clone LICKLAU-RLI 172.4 against CD4+ T cells (18), clone
3.155 against CD8' T cells (19), and sheep anti-mouse Ig poly-
clonal antibodies against B cells (Biosys, Compi6gne, France).
Fluorescein-conjugated antibodies from the following clones were
used as monitoring reagents : clone 30-H12, antiThy-1.2* (20) ;
clone GK1.5, anti-CD4* (21) ; clone 53-6.7, anti-CD8* (20);
clone MARK-1, anti-rat K chain (Biosys); and affinity-purified
anti-mouse Ig antibodies (Biosys) .
Statistical Analysis
Within each experimental group, theone-way variance analysis
test was used after verification of homogeneity of the variances by
Bartlett's test, andsubsequently, themeans were compared using
Duncan's and/or Tukey's test . When necessary, an inverse transfor-
mation of the survival times was performed to homogenize the
variances.
Results
Effect ofIFN-a//3 Treatment on the Survival Time ofDBA/2
Mice Injected Intravenously with 308FLC. 10 experiments
have been undertaken to determine the effect of IFN-a/0
treatment on the evolution ofFLC tumors and the survival
time of DBA/2 mice injected with 2 x 106 3C18 FLC
(equivalent ofN5 x 105 LD50 [1]) . The overall mean sur-
vival times were 8.7 ± 0.1 d for 115 untreated or control-
treated mice, and 64.5 ± 10.1 d for 95 mice treated with
at least 8 x 105 U of IFN-a/(3 daily for at least 1mo (Fig .
2) . Allcontrol FLC-injected mice died with characteristic mas-
sive tumor involvement of the liver and spleen (1) . Of the
95 IFN-treated mice, 46 died withtumorinvolvementofthe
liver and spleen ; 32 mice had no gross tumor involvement
of the liver and spleen but had tumor involvement of differ-
ent organs (kidney, ovaries, submaxillary, retroaortic and
retroperitoneallymph nodes, meninges, and vertebralcolumn);
and 11 mice were found dead without any detectable gross
tumor. The mean day of death for IFN-treated mice dying
with tumor in the liver and spleen was 54.0 ± 12.3 d, and
was 71.4 ± 18.0 d for mice dying without tumor in these
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Figure 1 .
￿
Tumorigenicity of 3C18 FLC injected intravenously in DBA/2
mice. 6-wk-old male DBA/2 mice were injected intravenously with 0.2
ml of 10-fold dilutions of 3C18 FLC . There were seven mice per 10-fold
dilution . The slope coefficient of the dose-response (day of death) line of
regression was highly significant (p < 0.001 ; 1/y = 9.98 x 10 - 3 Ln x
+ 150.10'z ; r = 0.741), with no significant deviation from linearity. The
means ± SE are indicated and were estimated after 1/y transformation
(y = day of death) .
Figure 2 .
￿
Effect ofIFN-ca/0 treatment on the survival time ofDBA/2
mice injected intravenously with 2 x 106 3C18 FLC . In all experiments,
IFN treatment was initiated 3 h after tumor injection (1) and continued
daily for at least 31 d and never beyond 72 d. Mice were injected in-
traperitoneally with different IFN-cr/,B preparations varying between 8
x 105 and 2 .4 x 106 U/mouse/d .organs but with tumor elsewhere or without gross tumor
(the difference was not significant) . Of 12 mice surviving
beyond 100 d (Fig. 2), three mice died at 110, 351, and 491
d with tumor involvement of the liver and spleen, whereas
three other mice had no detectabletumor when killed at 150
or 812 d or found dead at 130 d . Six other mice are still alive.
Some FLC-injected IFN-treated mice appeared clinically
well, but when killed were found on gross or microscopic
examination to harbor tumor cells in some organs. Fig . 3
shows a focus of FLC in the liver of a DBA/2 mouse killed
63 d after intravenous inoculation of 3C18 FLC . No inflam-
matory host reaction was seen within or in proximity to these
tumor foci .
These experimental results and those previously reported
(1, 7) suggested that host mechanisms were responsible for
continued suppression of tumor growth in various organs.
To characterize the nature of these mechanisms, we under-
took a series ofpassive transfer experiments using either sera
or spleen cells from surviving FLC-injected, IFN-treated mice.
In the experiments to be described, sera or spleen cells were
taken from IFN-treated mice without gross evidence oftumor
18-154 d after inoculation of FLC .
Serafrom FLC-injectedIFN-treated Mice Can Transfer Protec-
tion to DBA/2 Mice Injected with FLC . As can be seen from
the pooled results of 11 experiments illustrated in Fig. 4 A,
a single injection of sera from surviving FLC-injected, IFN-
treated mice conferred a marked protection on DBA/2 mice
when injected intravenously 18-24 h before an intravenous
challenge with FLC. Considering all the results together, the
mean day of death was 13.5 t 0.2 d for 66 untreated mice;
13.1 t 0.2 d for 41 mice treated with normal sera; and 19.0
± 0.6 d for 65 mice treated with sera from FLC-injected,
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Figure 3 .
￿
Morphologic appearance ofa focus ofFLC-
(delimited by arrows) persisting in the liver ofan IFN-
treated mouse killed 63 d after intravenous inocula-
tion of 2 x 10 6 308 PLC and treated in-
traperitoneally daily for 1 mo with 1 .6 x 106 U of
mouse IFN-tx/0. Hematoxylin and eosin (x600) .
IFN-treated mice (p < 0.001) . Analysis of each of the 11 ex-
periments showed a highly significant (p < 0.001) difference
in each experiment between the group of mice injected with
sera from FLC-injected, IFN-treated mice and the two con-
trol groups of mice.
Kinetic experiments showed that the protective factor was
not present in the sera of FLC-injected, IFN-treated mice 7
d after inoculation of the tumor (data not shown) but was
present in sera from mice 18-58 d after inoculation of FLC
in all 11 experiments. Sera from mice treated with IFN but
not injected with FLC did not confer protection on DBA/2
mice (Fig. 4 A) . Sera that protected mice against challenge
with PLC did not protect DBA/2 mice challenged intrave-
nously with methylcholanthrene-induced ESblymphoma cells
(Fig . 4 A) .
Protection was also observed when sera from FLC-injected
IFN-treated mice were mixed with FLC and injected sub-
cutaneously (Fig. 5A) or intraperitoneally (data not shown) .
Transfer ofSpleen Cells also Confers Protection.
￿
As can be
seen from the pooled results of seven experiments illustrated
in Fig . 4 B, spleen cells from FLC-injected, IFN-treated mice
conferred some degree of protection on DBA/2 mice when
injected intravenously 18-24 h before challenge with FLC.
Considering all the results together, the mean day of death
was 13.3 t 0.2 d for 38 untreated mice; 13.5 t 0.2 for 38
mice injected with normal mouse spleen cells; and 16.3 t
0.7 d for 51 mice injected with spleen cells from FLC-injected,
IFN-treated mice (p < 0.001) . Analysis of the results of each
individual experiment showed a highly significant difference
(p < 0.001) in five experiments between the protection in-
duced in mice receiving spleen cells from FLC-injected, IFN-
treated mice and the two groups ofcontrol mice. No significant
Immune Mechanisms Suppressing Friend Erythroleukemia MetastasesA Serum
￿
B Spleen cells
difference was observed between experimental and control
groups in two other experiments.
In four experiments, spleen cells from PLC-injected, IFN-
treated mice were mixed with 308 FLC in ratios of 75:1
to 133:1 and injected subcutaneously. As seen from the results
of an experiment illustrated in Fig. 5 B, a clear-cut inhibi-
tion in the development of subcutaneous FLC tumors was
observed compared with the two groups of control FLC-
injected mice .
Presence ofAntibodies to FLC in the Sera ofSurviving FLC-
injected IFN-treated Mice. We first determined the presence
ofantibodies to PLC in FLC-injected, IFN-treated mice using
a radioimmune binding assay. 19 of 20 IFN-treated mice de-
veloped significant antibodies to FLC, whereas untreated FLC-
injected DBA/2 mice had not developed antibodies to FLC
by the time of death (7-14 d) (Fig . 6) .
As shown in Fig. 7, sera from surviving mice exerted a
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Figure 4.
￿
Capacity of sera or spleen cells from surviving FLC-injected, IFN-treated mice to confer protection on DBA/2 mice injected intravenously
with 3C18 PLC. In 11 experiments, male or female adult DBA/2 mice were injected intravenously with 2 x 106 3C18 PLC and treated daily for
at least 3 wk with mouse IFN-ot/)3 (;~ 8 x 105 U/mouse/d) . 18-154 d thereafter, surviving mice were killed and sera or spleen cells from mice without
gross evidence of tumor were injected intravenously into normal adult male or female DBA/2 mice. In each experiment, other groups of mice were
injected with normal DBA/2 mouse sera or spleen cells or left untreated . 18-24 h later, all mice were injected intravenously with 8 x 104 to 1.6
x 105 3C18 FLC (ti2-4 x 104 LDso) . The mean day ofdeath offive to six untreated mice in each experiment was taken as the baseline (solid horizontal
line) . The day of death of serum-treated mice or mice injected with spleen cells is plotted in relation to the mean survival time of the untreated mice
in each experiment . Each symbol represents, therefore, an individual serum-treated or spleen cell-injected mouse challenged with 3C18 FLC. (A) In-
dividual serum samples or pools of sera from 3-16 PLC-injected, IFN-treated mice were injected (0.2 ml of undiluted sera) into 65 adult DBA/2 mice
(") . Sera from normal DBA/2 mice (O) or mice treated with IFN-ot/o but not injected with FLC (A) were injected into 41 or 5 other DBA/2
mice, respectively. DBA/2 mice receiving sera from FLC-injected, IFN-treated mice but challenged intravenously with 6 x 104 ESb lymphoma cells
are indicated (,~>) . The survival of these mice was compared with that of untreated mice injected with ESb cells. (B) Between 1 and 2 x 107 spleen
cells from surviving FLC-injected, IFN-treated mice were injected (in 0 .2 ml) into 51 normal adult DBA/2 mice (" ) . Spleen cells from normal mice
(O) or mice treated with IFN-a/o but not injected with FLC (A) were injected into 38 or 6 other DBA/2 mice, respectively.
clear-cut cytotoxicity on FLC target cells in the presence of
complement . Sera from untreated mice or mice injected only
withIFN were totally devoid ofcytotoxic activity. Thus, the
presence ofcomplement-fixing antibodies resulted from specific
immunization of the host against membrane-bound antigens
expressed on FLC cells .
By Western blotting, a pool of sera from FLC-injected,
IFN-treated mice exhibited a strong reactivity to specificPLC
membrane antigen(s) in the 65-kD region of the gel (Fig .
8) but did not react with cell surface membrane proteins from
other mouse tumor cells (i .e., RBIr5 and ESb cells) or normal
DBA/2 spleen cells (Fig . 8) . Sera from control FLC-injected
mice did not detect the 65-kD antigen(s) (Fig . 8) .
Evidence that theAnti-FLC Factor in the Sera ofac-injected
IFN-treated Mice Is an IS. The capacity ofthese sera to confer
protection on DBA/2 mice challenged intravenously with
FLC was abrogated by preincubation with 2 x 108 FLC forE
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2 h at 4°C . Thus, the mean day ofdeath of five control FLC-
injected mice was 12.1 ± 0.5 d vs. 17.0 ± 1.6 d for five
mice pre-injected with sera from FLC-injected, IFN-treated
mice (p <0.001) . In contrast, when this latter serum was
preincubated with FLC, the mean survival time of five recip-
ient mice was reduced to 13.2 ± 0.8 d, a difference that was
significant compared with the mean survival time of mice
injected with unabsorbed sera. Preincubation of a protective
serum with 2 x 108 normal DBA/2 spleen cells under the
same conditions did not diminish the protective activity of
the serum .
We could show that the protective serum factor was an
Ig by incubating serum from FLC-injected, IFN-treated mice
with protein A coupled to Sepharose 4B. Thus, as can be
16
12
4
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Figure 5 .
￿
The inhibitory effect of sera or spleen cells from FLC-injected, IFN-treated mice on the growth of 3C18 PLC injected subcutaneously.
Sera and spleen cells were obtained from 13 IFN-treated DBA/2 mice without gross evidence of tumor 32 d after intravenous inoculation of 3C18
FLC. (A) The pool of sera used in this experiment had been shown to be highly effective when injected intravenously in protecting mice challenged
with FLC intravenously. In this experiment, 1:2 and 1:6 dilutions of sera were mixed in equal volumes with 3C18 FLC for 15 min at room temperature
before injection . 5-wk-old female DBA/2 mice were injected subcutaneously with 0.2 ml of the mixture containing 2 x 105 3C18 PLC (i .e., ti2 x
103 LDso when injected subcutaneously), There were five mice in the group injected with a 1 :4 final dilution of this pool of sera and FLC (0), and
five mice in the group injected with a 1:12 final dilution of sera and FLC (/) . The 3 of 10 mice in these two groups developing tumors (one mouse
at the 1 :4 dilution and two at the 1:12 dilution of sera) are indicated (- - - -) . In another group of five mice, a 1:4 final dilution of normal mouse
sera was mixed withFLC (O), and in a third group of five mice, BSA (100 Ag/ml) was mixed with PLC (A) . All 10 control injected mice developed
subcutaneous tumors and died at 34.2 t 2 .9 and 35.9 ± 1.0 d with tumor metastases in the liver and spleen. Only 1 of 5 mice injected with PLC
and a 1:4 dilution of protective sera and 2 of 5 mice at a 1:12 dilution of sera developing tumors died with tumor metastases . The remaining seven
mice did not develop tumors and were tumor free when killed at 87 d. (B) 2 x 108 spleen cells/ml from FLC-injected, IFN-treated (" ) or normal
DBA/2 (O) mice were mixed in equal volumes with 1 .5 x 106 3C18 PLC/ml and 0.2 ml of the mixture injected subcutaneously into 7-wk-old male
DBA/2 mice. Each mouse received 1 .5 x 10 5 3C18 FLC, which was x+1.5 x 103 LDso) . There were eight mice per group. Another group of eight
mice (A) was injected with FLC mixed with cell culture medium containing 2% FCS. In the group receiving spleen cells and PLC from FLC-injected,
IFN-treated mice, four mice developed tumors asindicated (--------), and four mice didnot develop subcutaneous tumors. All 16 control PLC-injected
mice died with tumor metastases in the liver and spleen (mean day of death for untreated and normal spleen cell treated mice was 29.4 ± 1.3 and
24 .9 x 1.8 d, respectively) . In contrast, 4 of 8 of the mice receiving spleen cells from FLC-injected, IFN-treated mice died with visceral metastases
(mean day ofdeath was 62 .4 ± 8 .1 d), and four mice were tumor free when killed 135 d after tumor inoculation . The symbols indicate mean tumor
diameter (mm) per group. The SE is shown by the bar when it exceeded the diameter of the symbol .
seen in Table 1, incubation with protein A-Sepharose depleted
the serum of its capacity to confer protection, whereas the
same serum incubated with BSASepharose retained its pro-
tective activity. The eluate from the protein A-Sepharose 4B
was dialyzed and applied to aMono Q anion-exchange column.
The material from the IgG peak demonstrated a significant
antitumor activity (Table 1) .
Analysis ofthe Efector Cells Responsible for Adoptive Protec-
tion . In an attempt to characterize the effector cells respon-
sible for protection, we undertook three experiments in which
spleen cells from tumor-free FLC-injected, IFN-treated mice
were subjected to various depletion procedures, including
removal of Ig+, or CD4+ or CD8+ lymphocytes. As shown
in Fig. 9, the depletion of Ig+, or CD4+ or CD8+ lym--a W280
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Figure 6 .
￿
Presence of antibodies to PLC in FLC-injected, IFN-treated
mice . 20 7-wk-old female DBA/2 mice were injected intravenously with
106 3C18 PLC. 3 h later and daily thereafter, mice were injected in-
traperitoneally with 10 6 U ofIFN-a/S (" ) or a control preparation (O).
Sera from three control-treated mice were taken 7 d after tumor cell injec-
tion. The mean day of death of the six control mice was 7.8 t 0.4 d.
Orbital venous blood was taken every 14 d from tagged individual mice
(a minimum of one sample to a maximum of six samples per mouse, de-
pending on the survival time ofeach mouse) . Sera were tested for the pres-
ence of antibodies to PLC as described in Materials and Methods. The
highest titer ofanti-PLC antibodies detected for each mouse (in the course
of the total observation period) is plotted against the survival time of the
same mouse.
1 :8 1 :16 1 :32 1 :64 1 :128 1 :256
Figure 7 .
￿
Cytotoxicityof serum from FLC-injected, IFN-treated DBA/2
mice for target 3C18 PLC . 7-wk-old female DBA/2 mice were injected
intravenously with 2 x 106 3C18 PLC and treated daily with 1.6-3.2 x
106 U of IFN-a/fl. 28 d later, blood was taken from a surviving mouse
(" ) . 34 d later, a pool of sera from 15 other FLC-injected, IFN-treated
mice without any visible tumor wasalso tested for cytotoxicity ("). Blood
was also taken from a normal mouse (O) and an IFN-treated mouse not
injected with PLC (A) . Each point represents the mean oftriplicate wells.
The SE was <5% .
Figure 8 .
￿
Western blot analysis ofsera from FLC-injected, IFN-treated
DBA/2 mice . Plasma membrane fractions were extracted from 3C18 FLC,
RBIr5 cells, ESb lymphoma cells, and spleen cells from untreated DBA/2
mice. Electrophoresis andWestern blot analysis wereperformed asdescribed
in Materials andMethods. Pooled sera from untreated or control preparation-
treated DBA/2 mice injected intravenously with 3C18 FLC were used as
a negativecontrol (taken 7-10 d after tumorcell injection) . Sera from PLC-
injected, IFN-treated mice were taken from a pool of 13 mice 32 d after
tumor cell inoculation . None of the mice had visible tumor. Molecular
weight markers were phosphorylase B (97,400) ; BSA (66,000); OVA
(45,000) ; carbonic anhydrase (31,000) ; soybean trypsin inhibitor (21,500) ;
and lysozyme (14,400).
phocytes did not modify the protective capacity of the re-
maining spleen cells as determined either by the delay in the
appearance of subcutaneous tumors or by the lower incidence
of mice with tumors (Fig. 9 A), or by a decrease in the size
of the tumors (Fig. 9 B) . In the same experiments, spleen
cells doubly depleted ofCD4+ and CD8+ lymphocytes or
CD4+ and Ig+ cells, or CD8+ and Ig+ lymphocytes still
exerted an anti-FLC activity (data not shown) . In another
experiment, sequential depletion of Ig+, CD4+, and CD8+
lymphocytes did not modify the protective capacity of the
remaining spleen cells (data not shown) . These results indi-
cated that the effector cells were neitherB norT lymphocytes.
Discussion
IFN-ct/a has proven very effective in inhibiting the devel-
opment ofvisceral metastases and in increasing survival time
even after the intravenous injection oflarge numbers ofFLC.
About 10-15% of treated mice were considered cured (Fig.
2) (1, 2) . The pattern of tumor growth in IFN-treated mice
was totally different from that observed in control mice.
Whereas the latter died rapidly with massive tumor involve-
ment of the liver and spleen, IFN-treated mice died months
later, some with tumor in the liver and spleen, and others
with tumor in the kidneys, meninges, vertebral column, and
lymph nodes. Many mice appeared clinically well for long
periods but when killed were found to harbor nests of tumor
cells in different organs. Thus, in most mice IFN therapy
resulted in a suppression of tumor growth rather than an eradi-(A) 0.75 ml of sera was mixed on a mechanical stirrer with 0.5 ml of protein A-Sepharose 4B gel or with BSA linked to Sepharose 4B for 1 h
at 4°C . The gels were centrifuged at 2,500 rpm for 15 min and the supernatants tested for anti-FLC activity in mice.
(B) Thebound fraction of the serumwas eluted from the protein A-Sepharose 4B gel with0.1M sodium citrate, pH 4.0, dialyzed (20mM Tris-HCI,
pH 7.7), and applied to a Mono Q (anion exchange) column (Pharmacia Fine Chemicals). Proteins were eluted with a linear NaCl gradient (0-0 .5
M) . Igs eluted ti 0.2 M NaCl . 2 ml of the concentrated material from the IgG peak (2 mg) was injected intravenously into mice to determine
anti-FLC activity .
` 7-wk-old male DBA/2 mice were injected intravenously with 0.2 ml of material to be tested . 1 h later, mice were injected intravenously with
105 3C18 FLC .
t 7-wk-old male DBA/2 mice were injected intravenously with 2 x 106 3C18 PLC and treated daily with 2.4 x 106U of IFN-a//3 . 22 d later,
sera from 13 mice without gross evidence of tumor were pooled .
sp < 0.001 .
lip < 0.01 .
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cation of tumor, andFLC persisted often in a latent stateeven
after IFN treatment had been discontinued .
Although IFN treatmentofsomehuman andmouse tumor
"
￿
cells in culture has resulted in areversion of the transformed
phenotype to anormal phenotype (22-24), we foundno evi-
dence that IFN treatment of mice resulted in a similar rever-
sion of the tumorigenic phenotype ofFLC. Thus, PLC re-
covered from the liverofON-treated mice conservedthesame
capacity to form colonies in agarose and to induce tumors
as the original FLC suspension (data not shown) . On the
other hand, havingshown that an intact immune system was u
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Figure 9.
￿
Inhibitory effect of depleted and undepleted populations of
splenic lymphocytes from FLC-injected, IFN-treated mice on the growth
of3C18 FLC tumors injected subgutaneously in DBA/2 mice. Thedonor
spleen cells were taken from 9-10-wk-old male DBA/2 mice injected in-
travenously with 2 x 106 3C18 FLC and treated daily intraperitoneally
with 2 x 106 U of IFN-a/A 29 d later, six mice without any visible
tumor were killed, and the spleen cells were depleted of Ig+, CD4* or
CD8 * lymphocytes by panning on antibody-coated plastic dishes .
Monitoring ofdepleted cell populations by flow cytometry showed <2%
ofcontaminating cells (see Methods and Materials) . The undepleted and
depleted spleen cell populations were mixed with PLC in a ratio of 50 :1
and injected subcutaneously . Therewere six or seven mice per group. The
symbols refer to mice injected with PLC and BSA (p); PLC and normal
spleen cells (O) ; and PLC and total spleen cells from FLC-injected, IFN-
treated mice (") . This total cell population was then depleted bypanning
of CD8* lymphocytes (A) ; CD4+ lymphocytes (*) ; and Ig+ lympho-
cytes (/) . (A) The percent of mice in each group developing subcuta-
neous tumors . (B) The mean tumor diameter ± SE for the mice with
tumors.
Table 1 .
Group
Abrogation of the Protective Capacity of Sera from FLC-injected, IFN-treated
Pretreatment of sera
Mice by Passage on
No . of mice"
Protein A-Sepharose 4B
Mean day of
death (±SE)
A Control - 6 14.7 ± 0.7
Protein A-Sepharose 4B 6 14.0
NS
± 0.3 1
Sera from FLC-injected,
IFN-treated micet
BSA-Sepharose 4B 6 23.8 ± 1.6 J
B Buffer - 5 12.8 ± 0.2
Eluate from protein - 5 14.2 ± 0.4
A-Sepharose 413; Mono Q
ANION exchange columnessential in achieving optimal therapeutic effects ofIFN early
after inoculation ofFLC (7), we postulated that theimmune
system was involved in the continued suppression of FLC
tumor in the months after tumor inoculation . The fact that
FLC remained quiescent in different organs indicated that
these host mechanisms probably operated at a systemic level .
To gain some insight into the possible effector mechanisms,
we undertook a series of adoptive transfer experiments using
either sera or spleen cells from FLC-injected, IFN-treated mice.
The potency of the anti-FLC effect of the serum from these
mice was evident when one considers that : (a) this effect was
demonstrable not only through close local contact of serum
with FLC in a Winn-type assay (Fig. 5 A), but also by sys-
temic administration of serum 18-24 h before the intrave-
nous injection ofFLC (Fig. 4 A) ; and (b) a single injection
of serum resulted in a mean increase of survival time of 6 d
(Fig. 4 A), which, extrapolating from the titration curves
ofFLC in normal mice (Fig. 1), was the equivalent of a 1,000-
fold decrease in the initial tumor load .
Several arguments indicate that the protective factor in the
serum ofFLC-injected, IFN-treated mice is an Ig. First, FLC-
injected, IFN-treated mice develop antibodies toFLC demon-
strable by radioimmunoassay (Fig. 6), complement-dependent
cytotoxicity (Fig. 7), and immunoblotting (Fig. 8) . Second,
the protective factor is tumor cell specific in that sera from
mice injected withIFN but not injected withFLC are ineffec-
tive in transferring protection and that sera protective against
FLC do not protect mice challenged with an unrelated tumor
(ESb) (Fig . 4 A) . Third, and most importantly, the protec-
tive factor can be absorbed out by preincubation with FLC ;
it binds to protein A-Sepharose and can be recovered in the
IgG fraction after elution from the protein A-Sepharose gel
column (Table 1) .
We can only speculate at present as to the nature of the
relevant FLC antigens that trigger the humoral response in
IFN-treated mice. The immunoblots indicated that sera from
3C18 FLC-injected, IFN-treated mice reacted with a 65-kD
cell surface protein(s) from FLC, not present on RBI,5 and
ESb cells or on normal spleen cells (Fig . 8) . The reactivity
of these sera with a protein(s) in the 65-kD region of the
gel could reflect the presence of antibodies to gp70-related
Friend leukemia virus proteins that are highly expressed on
the cell membrane of 3C18 FLC (25) . However, these sera
also reacted with membrane preparations from a Friend
leukemia virus nonproducer cell line (745) (data not shown)
that does not express the gp70 antigen (25), suggesting that
these micemay be reacting to tumor-specific antigenscommon
to FLC lines.
We thank Miss M . Lecuyer for skillful technical assistance .
Spleen cells from FLC-injected, IFN-treated mice also medi-
ated protection against FLC when transferred both systemi-
cally (Fig. 4 B) or locally in Winn assays together with FLC
(Fig. 5 B) . Analysis ofthe cell separation experiments aimed
at identifying the effector cells showed that neither the deple-
tion ofT lymphocytes nor B lymphocytes reduced the pro-
tective potential of spleen cells from FLC-injected, IFN-treated
mice (Fig . 9) . It was therefore deduced that T and B lym-
phocytes did not directly participate in tumor suppression,
at least at the effector stage of the process, and that nul cells
were most probably responsible for passive transfer of pro-
tection .
One of the major questions posed by our experiments con-
cerns the role of IFN in the promotion of an immune re-
sponse to FLC . IFN might enhance the humoral immune
response itself or the effector mechanisms . There are a few
examples ofthe enhancing effect ofIFN-a/(3 on the primary
antibody response of mice to sheep erythrocytes (26) and to
rabies virus vaccine (27), but we are unaware of any pub-
lished reports on the effects ofIFN on the antibody response
to tumor antigens. On the other hand ;IFN might also affect
the effector stage of the response by enhancing the expres-
sion of Fcy receptors on lymphocytes (28) . A third possi-
bility would be that by exerting an antitumor effect, IFN
treatment permitted the mouse to survive long enough to
develop an immune response.
The experimental results presented herein on the mecha-
nisms operative in the IFN-a/(3-induced continued suppres-
sion of FLC tumor growth may be relevant to the use of
IFN-a in patients with different forms of cancer. Thus, al-
though IFN-a has induced remissions and tumor regression
in some patients, tumor cells often remain latent for extended
periods of time without being eradicated (29), suggesting
that host mechanisms, humoral and/or cellular, maintain a
continued suppression oftumor growth . It is also ofinterest
that IFN-a appears to inhibit some tumors in which defined
tumor antigens have been described, i.e., melanoma and renal
cell carcinoma (30-32) . It would be of interest to know
whetherIFN treatment affects the antibody response of these
patients to tumor antigens, and if so, whether there is any
correlation between a beneficial response toIFN therapy and
the antibody response. The efficacy of IFN-a therapy may
be related not only to the multiple effects of IFN on the
tumor or the host, but also to the immunogenicity of a given
tumor and the capacity ofantibody or effector cells to reach
the tumor.
This work was supported by grants from the CNRS, the Association pour la Recherche sur le Cancer,
the CEE (SCI-0234), INSERM (87-1008), the Foundation pour la Recherche Medicale, the Programma
Italia-USA sulla Terapia dei Tumori (1989), and the Associazione Italiana per la Ricerca sul Canceo.
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